Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 1.00 |
| ▸ | SYK | P43405 | 8/20 | 0.92 |
| ▸ | AURKA | O14965 | 6/20 | 0.65 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2217640 | 1.00 | BTK (1.00) | BTKSYKAURKAEPHB4ALDH1A1 | |
| SCHEMBL2218484 | 0.96 | SYK (1.00) | BTKSYKAURKAEPHB4 | |
| SCHEMBL2219062 | 0.95 | BTK (0.90) | BTKSYKAURKAEPHB4 | |
| SCHEMBL4816119 | 0.94 | BTK (0.89) | BTKSYKAURKAEPHB4 | |
| SCHEMBL6002791 | 0.94 | BTK (0.89) | BTKSYKAURKAEPHB4 | |
| SCHEMBL4811490 | 0.94 | BTK (0.89) | BTKSYKAURKAEPHB4 | |
| SCHEMBL2216718 | 0.94 | BTK (0.89) | BTKSYKAURKAEPHB4 | |
| SCHEMBL4808482 | 0.94 | BTK (0.88) | BTKSYKAURKAEPHB4ALDH1A1 | |
| SCHEMBL2217123 | 0.93 | BTK (0.87) | BTKSYKAURKAEPHB4 | |
| SCHEMBL2218534 | 0.93 | BTK (0.87) | BTKSYKAURKAEPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| US-12534472-B2 | Morphic forms of trilaciclib and methods of manufacture thereof | PHARMACOSMOS HOLDING A/S (DK) | 2026-01-27 | — | — | US | disclosed |
| US-20260014157-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | PHARMACYCLICS LLC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260014160-A1 | G1T38 SUPERIOR DOSAGE REGIMES | PHARMACOSMOS HOLDING A/S (DK) | 2026-01-15 | — | — | US | disclosed |
| US-12454539-B2 | Controlled-delivery cromakalim prodrugs | QLARIS BIO, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250319091-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250243212-A1 | MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF | PHARMACOSMOS HOLDING A/S (DK) | 2025-07-31 | — | — | US | disclosed |
| WO-2025137605-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR | C4 THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025129116-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-4114392-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 Therapeutics, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-4100003-A1 | IMPROVED METHODS AND COMPOSITIONS FOR CROMAKALIM PRODRUG THERAPY | Qlaris Bio, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022251539-A2 | EGFR DEGRADERS TO TREAT CANCER METASTASIS TO THE BRAIN OR CNS | C4 THERAPEUTICS, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| EP-4076450-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| EP-4072543-A1 | CONTROLLED-DELIVERY CROMAKALIM PRODRUGS | Qlaris Bio, Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| US-20220249494-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | PHARMACYCLICS LLC (US) | 2022-08-11 | — | — | US | disclosed |
| US-20220175785-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | PHARMACYCLICS LLC (US) | 2022-06-09 | — | — | US | disclosed |
| WO-2022066774-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022032026-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014160-A1 | G1T38 SUPERIOR DOSAGE REGIMES | CDK4, CCND1, CDK8 | BTK 123/4885SYK 301/4885AURKA 201/4885 |
| US-20260014157-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | BTK, BCL6B, BCL9 | BTK 1/4885SYK 10/4885AURKA 922/4885 |
| US-20220249494-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | BTK, LYN, SYK | BTK 1/4885SYK 3/4885AURKA 437/4885 |
| US-12454539-B2 | Controlled-delivery cromakalim prodrugs | KCNJ1, KCNJ8, KCNJ11 | BTK 2596/4885SYK 2892/4885AURKA 567/4885 |
| US-20250319091-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | BTK 55/4885SYK 736/4885AURKA 347/4885 |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | BTK 1148/4885SYK 3539/4885AURKA 907/4885 |
| US-20220175785-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | BTK, LYN, SYK | BTK 1/4885SYK 3/4885AURKA 437/4885 |
| US-20250243212-A1 | MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF | MCL1, ETV6, ALK | BTK 645/4885SYK 947/4885AURKA 1144/4885 |
| US-12534472-B2 | Morphic forms of trilaciclib and methods of manufacture thereof | CTNND1, FLT3, MEF2D | BTK 167/4885SYK 313/4885AURKA 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.